This profile has not been claimed and data may not be accurate.
48th percentile
Serial biotech founder and UCI professor leading Aureka's $35M AI-drug-discovery platform
Credibility
Domain Expertise · 85th percentile
- Deep research credibility: h-index 52 and 12,183 citations across published works (OpenAlex).
- Identified researcher on OpenAlex with 150 published works.
Relationship Matrix
Most Like You
Most Complimentary
Founder score
- 97%Probability of being accurate (97%)Current Founder and CEO of Aureka Biotechnologies Inc.
- 90%Probability of being accurate (90%)Aureka Biotechnologies raised $35M in its Series A+ financing round.
- 88%Probability of being accurate (88%)Past founder of Velox Biosystems and Arvetas Biosciences.
- 85%Probability of being accurate (85%)Deep research credibility: h-index 52 and 12,183 citations across published works (OpenAlex).
- 85%Probability of being accurate (85%)Identified researcher on OpenAlex with 150 published works.
- 80%Probability of being accurate (80%)Aureka Biotechnologies and prior companies were co-founded with other founders.
What you likely need
You'd get the most out of Festival events that put you in the room with late-stage biotech investors and Big Pharma BD leads who can accelerate your Series B narrative and validate Aureka's agentic platform commercially. Curated dinners bridging the AI-drug-discovery and pharma-partnership worlds — especially with a China biotech angle given your Qiming and HSG backing — would open the highest-leverage doors right now. Smaller, peer-level gatherings with other founder-professors would also help you protect your energy during this critical scale-up phase.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- fundraisingA Series B-stage AI-biotech founder dinner with partners from Qiming, HSG, and MPCi portfolio companies to pressure-test Aureka's platform milestone narrative and anchor a compelling growth story for the next raise
- tacticalA closed-door roundtable with BD and alliance management leads from top-20 pharma companies (Pfizer, AstraZeneca, Roche) actively scouting AI-driven antibody discovery co-development deals to accelerate Aureka's first paid licensing partnership
- introsA Qiming and HSG LP-network dinner connecting Aureka with Chinese pharma and biotech executives — BeiGene, Zymeworks, Zai Lab — to explore licensing and co-development deals through Aureka's existing China presence
- hiringA hiring dinner for AI-biotech founders scaling past 20 employees to trade candidate pipelines and warm referrals for VP of Business Development and Chief Scientific Officer roles across the Andreessen Bio and MPCi portfolio networks
- positioningAn MIT TR35 and academic-founder roundtable with other scientist-CEOs (h-index 40+) navigating the tension between high-impact journal publishing and startup commercialization, to sharpen Aureka's platform validation publication strategy
- tacticalA tactical half-day offsite for founders running complementary AI-biology platforms — anchored around Amberstone Biosciences' single-cell discovery capabilities — to map concrete integration paths that could create a differentiated end-to-end antibody pipeline
- wellbeingA small wellbeing dinner for active founder-professors at Series A+ stage to share concrete boundary-setting frameworks and delegation playbooks for protecting research output without sacrificing startup momentum